NASDAQ:OMER - Omeros Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.63 +0.78 (+5.63 %)
(As of 12/11/2018 03:37 PM ET)
Previous Close$13.85
Today's Range$13.64 - $14.63
52-Week Range$8.36 - $27.00
Volume15,804 shs
Average Volume678,096 shs
Market Capitalization$687.11 million
P/E Ratio-17.86
Dividend YieldN/A
Beta3.91
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Its clinical programs include OMS721 that is in Phase III clinical trial for treating immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA), and atypical hemolytic uremic syndrome (aHUS); and in Phase II clinical trial to treat IgA nephropathy, membranous nephropathy, lupus nephritis, and complement component glomerulopathy. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for treating Huntington's diseases and schizophrenia; and OMS405 that is in Phase II clinical trial to treat opioids, nicotine, and alcohol addiction. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; and OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. The company's preclinical programs also include MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HCT-TMA, and age-related macular degeneration; MASP-3-small-molecule inhibitors used for the treatment of PNH and other alternative pathway disorders; G protein-coupled receptor (GPCR) platform, including GPR174 and other Class A orphan GPCRS for treating CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal and other disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:OMER
Previous Symbol
CUSIP68214310
Phone206-676-5000

Debt

Debt-to-Equity RatioN/A
Current Ratio2.69
Quick Ratio2.68

Price-To-Earnings

Trailing P/E Ratio-17.86
Forward P/E Ratio-5.78
P/E GrowthN/A

Sales & Book Value

Annual Sales$64.83 million
Price / Sales11.06
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.06) per share
Price / Book-243.83

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-53,480,000.00
Net Margins-554.22%
Return on EquityN/A
Return on Assets-104.70%

Miscellaneous

Employees173
Outstanding Shares49,010,000
Market Cap$687.11 million
OptionableOptionable

Omeros (NASDAQ:OMER) Frequently Asked Questions

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) posted its quarterly earnings data on Friday, November, 9th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.77) by $0.04. The biopharmaceutical company had revenue of $4.61 million for the quarter, compared to analysts' expectations of $3.07 million. During the same period last year, the business posted ($0.16) EPS. View Omeros' Earnings History.

When is Omeros' next earnings date?

Omeros is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Omeros.

What price target have analysts set for OMER?

7 brokerages have issued 12 month price targets for Omeros' stock. Their forecasts range from $4.00 to $75.00. On average, they anticipate Omeros' stock price to reach $27.8763 in the next twelve months. This suggests a possible upside of 90.5% from the stock's current price. View Analyst Price Targets for Omeros.

What is the consensus analysts' recommendation for Omeros?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omeros.

What are Wall Street analysts saying about Omeros stock?

Here are some recent quotes from research analysts about Omeros stock:
  • 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We currently ascribe a total firm value of roughly $2.3B to Omeros based on OMIDRIA ($820M) and OMS721 ($1.5B). This translates into a target of $34.00 per share, based on 68M fully-diluted shares outstanding as of end-2019. We assume the redemption of the senior convertible notes in full after one year, using proceeds from a follow-on offering of common stock in late 2019." (12/4/2018)
  • 2. Maxim Group analysts commented, "Omeros reported 3Q18 with $4.6M in Omidria revenues, up from $1.7M in 2Q18. Omeros reported a net loss for the quarter of ($39.5M), and a cash balance of $55M, excluding the $210M debt offering announced concurrently. OMER shares are down ~20%, in our view, due to a misunderstanding of the financing." (11/9/2018)
  • 3. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (10/9/2018)

Has Omeros been receiving favorable news coverage?

News headlines about OMER stock have trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Omeros earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term.

Who are some of Omeros' key competitors?

Who are Omeros' key executives?

Omeros' management team includes the folowing people:
  • Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 59)
  • Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 60)
  • Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 58)
  • Dr. Pamela Pierce Palmer, Co-Founder (Age 55)
  • Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 61)

Who are Omeros' major shareholders?

Omeros' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (10.84%), BlackRock Inc. (8.15%), Vanguard Group Inc. (4.50%), Cpwm LLC (1.62%), Foresite Capital Management IV LLC (0.73%) and Morgan Stanley (0.58%). Company insiders that own Omeros stock include Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros.

Which institutional investors are selling Omeros stock?

OMER stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Cpwm LLC, Wedbush Securities Inc., Credit Suisse AG, Baird Financial Group Inc., Mesirow Financial Investment Management Inc., Nwam LLC and Sheaff Brock Investment Advisors LLC. Company insiders that have sold Omeros company stock in the last year include Marcia S Kelbon and Michael A Jacobsen. View Insider Buying and Selling for Omeros.

Which institutional investors are buying Omeros stock?

OMER stock was acquired by a variety of institutional investors in the last quarter, including Foresite Capital Management IV LLC, BlackRock Inc., Vanguard Group Inc., Teachers Advisors LLC, WealthTrust Axiom LLC, Fox Run Management L.L.C., Alps Advisors Inc. and Advisors Asset Management Inc.. View Insider Buying and Selling for Omeros.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $14.63.

How big of a company is Omeros?

Omeros has a market capitalization of $687.11 million and generates $64.83 million in revenue each year. The biopharmaceutical company earns $-53,480,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Omeros employs 173 workers across the globe.

What is Omeros' official website?

The official website for Omeros is http://www.omeros.com.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.


MarketBeat Community Rating for Omeros (NASDAQ OMER)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  538 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  852
MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel